\-\ Texto\\:\\ \ \(0\)\
\-\ afebrile\ \(65\)\
\-\ heart\\ rate\\ 96\ \(0\)\
\-\ bp\\ 131\\/90\ \(0\)\
\-\ spo2\\ 98\\%\ \(0\)\
\-\ physical\\ exam\\ significant\\ for\\ rales\\ bilaterally\\ in\\ the\\ lungs\\.\ \(0\)\
\-\ while\\ in\\ the\\ hospital\\,\\ the\\ patient\\ was\\ treated\\ with\\ a\\ gentle\\ diuresis\\.\\ \\ medications\\ including\\ an\\ ace\\-inhibitor\\ and\\ beta\\ blocker\\ were\\ initiated\\ during\\ hospitalization\\ and\\ were\\ to\\ be\\ continued\\ at\\ discharge\\.\\ \\ obstretrics\\ and\\ gynecology\\ advised\\ long\\-term\\ contraception\\ and\\ counseled\\ patient\\ as\\ to\\ the\\ need\\ of\\ avoiding\\ future\\ pregnancy\\ which\\ could\\ be\\ life\\-threatening\\.\\ \\ the\\ patient\\ was\\ to\\ follow\\-up\\ with\\ her\\ primary\\ care\\ physician\\ and\\ pulmonologist\\ in\\ 4\\ weeks\\.\ \(0\)\
\-\ chest\\ radiograph\\ demonstrates\\ cardiac\\ enlargement\\ and\\ vascular\\ prominence\\ and\\ opacity\\ of\\ the\\ right\\ lower\\ lung\\.\\ \\ \ \(0\)\
\-\ ct\\ demonstrates\\ cardiac\\ enlargement\\ with\\ dilated\\ left\\ ventricle\\ and\\ small\\ bilateral\\ pleural\\ effusions\\ as\\ well\\ as\\ patchy\\ areas\\ of\\ airspace\\ consolidation\\ bilaterally\\,\\ compatible\\ with\\ diffuse\\ alveolar\\ hemorrhage\\.\\ \ \(0\)\
\-\ tte\\ shows\\ severe\\ apical\\ and\\ periapical\\ hypokinesia\\ with\\ an\\ ef\\ of\\ only\\ 10\\-15\\%\\.\ \(0\)\
\-\ peripartum\\ cardiomyopathy\ \(3\)\
\-\ \\â\\€\\¢peripartum\\ cardiomyopathy\\,\\ with\\ diffuse\\ alveolar\\ hemorrhage\\ due\\ to\\ acute\\ onset\\ severe\\ lv\\ dysfunction\ \(0\)\
\-\ \\â\\€\\¢cardiomyopathy\\ of\\ other\\ cause\\,\\ with\\ patchy\\ consolidation\\ due\\ to\\ pneumonia\\ or\\ hemorrhage\\ associated\\ with\\ immune\\ disorder\ \(0\)\
\-\ 22\\ year\\ old\\ g1p1\\ presents\\ with\\ hemoptysis\\ and\\ shortness\\ of\\ breath\\ for\\ 1\\ day\\.\\ \\ she\\ is\\ 8\\ days\\ post\\ induced\\ labor\\ and\\ delivery\\ at\\ 36\\ weeks\\ due\\ to\\ pre\\-eclampsia\\ and\\ was\\ discharged\\ 2\\ days\\ ago\\ on\\ beta\\ blocker\\ and\\ clonidine\\ patch\\.\ \(0\)\
\-\ this\\ patient\\ demonstrated\\ new\\ onset\\ of\\ cardiac\\ enlargement\\ with\\ left\\ ventricular\\ dilatation\\ and\\ severely\\ reduced\\ ejection\\ fraction\\ to\\ 10\\-15\\%\\ approximately\\ 1\\ week\\ after\\ labor\\ and\\ delivery\\.\\ \\ given\\ no\\ other\\ predisposing\\ factors\\ for\\ cardiomyopathy\\ and\\ timing\\ of\\ onset\\,\\ the\\ patient\\ was\\ diagnosed\\ with\\ peripartum\\ cardiomyopathy\\.\\ \\ this\\ patient\\ suffered\\ from\\ pre\\-eclampia\\ during\\ and\\ after\\ her\\ pregnancy\\,\\ which\\ is\\ has\\ been\\ reported\\ as\\ a\\ risk\\ factor\\ for\\ peripartum\\ cardiomyopathy\\.\\ \\ imaging\\ demonstrated\\ evidence\\ of\\ diffuse\\ alveolar\\ hemorrhage\\ which\\ was\\ determined\\ to\\ be\\ due\\ to\\ rapid\\ onset\\ of\\ pulmonary\\ venous\\ hypertension\\ associated\\ with\\ the\\ acute\\ development\\ of\\ severe\\ left\\ ventricular\\ dysfunction\\ as\\ immune\\ workup\\ and\\ bronchoscopy\\ were\\ negative\\ for\\ another\\ cause\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cardiomyopathy\\:\\ 0\\.08739154374735006\ \(0\)\
\-\ peripartum\\:\\ 0\\.07187939153457126\ \(0\)\
\-\ blocker\\:\\ 0\\.05200895825348967\ \(0\)\
\-\ alveolar\\:\\ 0\\.04514996776338222\ \(0\)\
\-\ labor\\:\\ 0\\.035651502665054374\ \(0\)\
\-\ beta\\:\\ 0\\.034956617498940024\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.03433502153635697\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.03356054966579393\ \(0\)\
\-\ immune\\:\\ 0\\.03351046730405515\ \(0\)\
\-\ onset\\:\\ 0\\.03182797906696342\ \(0\)\
\-\ enlargement\\:\\ 0\\.0300050301458858\ \(0\)\
\-\ cardiac\\:\\ 0\\.02880386542434487\ \(0\)\
\-\ patchy\\:\\ 0\\.02702897887533474\ \(0\)\
\-\ due\\:\\ 0\\.026905925108588077\ \(0\)\
\-\ dysfunction\\:\\ 0\\.02686040440663825\ \(0\)\
\-\ 131\\/90\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ ace\\-inhibitor\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ obstretrics\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ \\â\\€\\¢peripartum\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ \\â\\€\\¢cardiomyopathy\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ pre\\-eclampia\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ delivery\\:\\ 0\\.02586844616591849\ \(0\)\
\-\ consolidation\\:\\ 0\\.025267958293883435\ \(0\)\
\-\ contraception\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ clonidine\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ severe\\:\\ 0\\.02326822831916818\ \(0\)\
\-\ diffuse\\:\\ 0\\.022893870976772698\ \(0\)\
\-\ ventricular\\:\\ 0\\.022526879942196952\ \(0\)\
\-\ diuresis\\:\\ 0\\.02191511522963601\ \(0\)\
\-\ life\\-threatening\\:\\ 0\\.02191511522963601\ \(0\)\
\-\ pregnancy\\:\\ 0\\.02167465998503739\ \(0\)\
\-\ gentle\\:\\ 0\\.02125687466528731\ \(0\)\
\-\ hypokinesia\\:\\ 0\\.02125687466528731\ \(0\)\
\-\ pre\\-eclampsia\\:\\ 0\\.02125687466528731\ \(0\)\
\-\ periapical\\:\\ 0\\.020719052963830215\ \(0\)\
\-\ ef\\:\\ 0\\.020719052963830215\ \(0\)\
\-\ counseled\\:\\ 0\\.020264331194428272\ \(0\)\
\-\ avoiding\\:\\ 0\\.020264331194428272\ \(0\)\
\-\ tte\\:\\ 0\\.0198704332810816\ \(0\)\
\-\ g1p1\\:\\ 0\\.01952299069802442\ \(0\)\
\-\ gynecology\\:\\ 0\\.019212192716732898\ \(0\)\
\-\ as\\:\\ 0\\.0190645649836892\ \(0\)\
\-\ pulmonologist\\:\\ 0\\.018931041743858783\ \(0\)\
\-\ timing\\:\\ 0\\.018438256833347967\ \(0\)\
\-\ lv\\:\\ 0\\.017825751332527187\ \(0\)\
\-\ predisposing\\:\\ 0\\.017825751332527187\ \(0\)\
\-\ \\%\\:\\ 0\\.017640009144654935\ \(0\)\
\-\ 96\\:\\ 0\\.017478308749470012\ \(0\)\
\-\ spo2\\:\\ 0\\.01731881842123911\ \(0\)\
\-\ patch\\:\\ 0\\.01731881842123911\ \(0\)\
\-\ were\\:\\ 0\\.017170675545928507\ \(0\)\
\-\ fraction\\:\\ 0\\.017167510768178487\ \(0\)\
\-\ cause\\:\\ 0\\.01705759661682576\ \(0\)\
\-\ bilaterally\\:\\ 0\\.016558732970642497\ \(0\)\
\-\ ejection\\:\\ 0\\.016393574884793555\ \(0\)\
\-\ advised\\:\\ 0\\.015874723361301923\ \(0\)\
\-\ hospitalization\\:\\ 0\\.015690297529498576\ \(0\)\
\-\ suffered\\:\\ 0\\.015690297529498576\ \(0\)\
\-\ 98\\:\\ 0\\.015602235691298929\ \(0\)\
\-\ initiated\\:\\ 0\\.01551672673297075\ \(0\)\
\-\ bronchoscopy\\:\\ 0\\.01551672673297075\ \(0\)\
\-\ days\\:\\ 0\\.01545176575912671\ \(0\)\
\-\ during\\:\\ 0\\.015427783185391198\ \(0\)\
\-\ severely\\:\\ 0\\.015352803868207296\ \(0\)\
\-\ airspace\\:\\ 0\\.015197512618987764\ \(0\)\
\-\ patient\\:\\ 0\\.015160919131263504\ \(0\)\
\-\ her\\:\\ 0\\.015158770846518795\ \(0\)\
\-\ induced\\:\\ 0\\.015122828819624075\ \(0\)\
\-\ prominence\\:\\ 0\\.014909493534728422\ \(0\)\
\-\ demonstrated\\:\\ 0\\.014793038244583879\ \(0\)\
\-\ was\\:\\ 0\\.014576364634420158\ \(0\)\
\-\ apical\\:\\ 0\\.014524183262111716\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.014524183262111716\ \(0\)\
\-\ weeks\\:\\ 0\\.014308423344549548\ \(0\)\
\-\ which\\:\\ 0\\.01411632378090751\ \(0\)\
\-\ future\\:\\ 0\\.013976345073925601\ \(0\)\
\-\ long\\-term\\:\\ 0\\.013926766553818283\ \(0\)\
\-\ compatible\\:\\ 0\\.013926766553818283\ \(0\)\
\-\ rales\\:\\ 0\\.013878007551012352\ \(0\)\
\-\ reduced\\:\\ 0\\.01326852598946958\ \(0\)\
\-\ determined\\:\\ 0\\.013152830670433352\ \(0\)\
\-\ workup\\:\\ 0\\.012969551080147197\ \(0\)\
\-\ effusions\\:\\ 0\\.012864811586174012\ \(0\)\
\-\ factor\\:\\ 0\\.012864811586174012\ \(0\)\
\-\ rapid\\:\\ 0\\.012730704288012488\ \(0\)\
\-\ 36\\:\\ 0\\.012633979146941718\ \(0\)\
\-\ need\\:\\ 0\\.012571213959781585\ \(0\)\
\-\ acute\\:\\ 0\\.012447665658445399\ \(0\)\
\-\ discharge\\:\\ 0\\.012220323272874901\ \(0\)\
\-\ 1\\:\\ 0\\.011996025769673787\ \(0\)\
\-\ associated\\:\\ 0\\.011896534288541014\ \(0\)\
\-\ physician\\:\\ 0\\.011882084605263871\ \(0\)\
\-\ opacity\\:\\ 0\\.011785359464193101\ \(0\)\
\-\ be\\:\\ 0\\.011661563923397603\ \(0\)\
\-\ afebrile\\:\\ 0\\.011645970423336035\ \(0\)\
\-\ other\\:\\ 0\\.011620286423023296\ \(0\)\
\-\ discharged\\:\\ 0\\.011556574112140373\ \(0\)\
\-\ to\\:\\ 0\\.011338091374592555\ \(0\)\
\-\ disorder\\:\\ 0\\.011323848618129568\ \(0\)\
\-\ factors\\:\\ 0\\.011323848618129568\ \(0\)\
\-\ medications\\:\\ 0\\.011243575569383596\ \(0\)\
\-\ 22\\:\\ 0\\.011243575569383596\ \(0\)\
\-\ demonstrates\\:\\ 0\\.011012514464030596\ \(0\)\
\-\ development\\:\\ 0\\.010978667324954974\ \(0\)\
\-\ bp\\:\\ 0\\.010942693068041055\ \(0\)\
\-\ continued\\:\\ 0\\.010854631229841405\ \(0\)\
\-\ another\\:\\ 0\\.010837329992518695\ \(0\)\
\-\ dilatation\\:\\ 0\\.010803028995482947\ \(0\)\
\-\ for\\:\\ 0\\.010753807502104943\ \(0\)\
\-\ shortness\\:\\ 0\\.010605199406749774\ \(0\)\
\-\ after\\:\\ 0\\.010430685561116239\ \(0\)\
\-\ pneumonia\\:\\ 0\\.010419807360556076\ \(0\)\
\-\ hypertension\\:\\ 0\\.009937407233923858\ \(0\)\
\-\ rate\\:\\ 0\\.009825137140046734\ \(0\)\
\-\ pleural\\:\\ 0\\.009788643653903528\ \(0\)\
\-\ and\\:\\ 0\\.009558000304365582\ \(0\)\
\-\ lungs\\:\\ 0\\.00954509910908636\ \(0\)\
\-\ hospital\\:\\ 0\\.00948996007365228\ \(0\)\
\-\ ventricle\\:\\ 0\\.009446579107900968\ \(0\)\
\-\ breath\\:\\ 0\\.009425125540558549\ \(0\)\
\-\ 8\\:\\ 0\\.009425125540558549\ \(0\)\
\-\ ago\\:\\ 0\\.009382680887307518\ \(0\)\
\-\ could\\:\\ 0\\.009299580955252367\ \(0\)\
\-\ diagnosed\\:\\ 0\\.009269012261932169\ \(0\)\
\-\ reported\\:\\ 0\\.009189011358630714\ \(0\)\
\-\ dilated\\:\\ 0\\.009159561671361735\ \(0\)\
\-\ venous\\:\\ 0\\.009149810083944334\ \(0\)\
\-\ risk\\:\\ 0\\.009130403089554828\ \(0\)\
\-\ including\\:\\ 0\\.009101529914433403\ \(0\)\
\-\ care\\:\\ 0\\.009091967985453546\ \(0\)\
\-\ new\\:\\ 0\\.008784035329795157\ \(0\)\
\-\ heart\\:\\ 0\\.008758347046928537\ \(0\)\
\-\ given\\:\\ 0\\.008641340390903664\ \(0\)\
\-\ week\\:\\ 0\\.008560517458195364\ \(0\)\
\-\ areas\\:\\ 0\\.008481850062672764\ \(0\)\
\-\ left\\:\\ 0\\.008461108577636413\ \(0\)\
\-\ vascular\\:\\ 0\\.008264906395055152\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.008200699089798648\ \(0\)\
\-\ radiograph\\:\\ 0\\.008029347061714934\ \(0\)\
\-\ day\\:\\ 0\\.008002831355023391\ \(0\)\
\-\ post\\:\\ 0\\.007937566469239803\ \(0\)\
\-\ while\\:\\ 0\\.007931118701629243\ \(0\)\
\-\ approximately\\:\\ 0\\.007798872644706734\ \(0\)\
\-\ only\\:\\ 0\\.007579385423259397\ \(0\)\
\-\ treated\\:\\ 0\\.007545282702312269\ \(0\)\
\-\ negative\\:\\ 0\\.0075283780571530215\ \(0\)\
\-\ primary\\:\\ 0\\.007467210215031553\ \(0\)\
\-\ pulmonary\\:\\ 0\\.007364455192389568\ \(0\)\
\-\ lung\\:\\ 0\\.007301354336987452\ \(0\)\
\-\ she\\:\\ 0\\.0070760653140241065\ \(0\)\
\-\ 4\\:\\ 0\\.007023515944480959\ \(0\)\
\-\ an\\:\\ 0\\.006971474125573627\ \(0\)\
\-\ shows\\:\\ 0\\.006930305898905247\ \(0\)\
\-\ been\\:\\ 0\\.006857802033817083\ \(0\)\
\-\ at\\:\\ 0\\.006830461078652702\ \(0\)\
\-\ significant\\:\\ 0\\.006778310180100953\ \(0\)\
\-\ evidence\\:\\ 0\\.00660897517217368\ \(0\)\
\-\ physical\\:\\ 0\\.006184381326198343\ \(0\)\
\-\ bilateral\\:\\ 0\\.006117456428656177\ \(0\)\
\-\ chest\\:\\ 0\\.006031648967721294\ \(0\)\
\-\ imaging\\:\\ 0\\.005905822491019477\ \(0\)\
\-\ small\\:\\ 0\\.00580700673858737\ \(0\)\
\-\ well\\:\\ 0\\.0057023036960727165\ \(0\)\
\-\ this\\:\\ 0\\.005670426037251522\ \(0\)\
\-\ lower\\:\\ 0\\.005669209644141187\ \(0\)\
\-\ exam\\:\\ 0\\.005537563244688903\ \(0\)\
\-\ 2\\:\\ 0\\.005428036862862968\ \(0\)\
\-\ presents\\:\\ 0\\.005149393202088277\ \(0\)\
\-\ \\,\\:\\ 0\\.004791328593226325\ \(0\)\
\-\ has\\:\\ 0\\.0047336282315465425\ \(0\)\
\-\ with\\:\\ 0\\.004141740746544769\ \(0\)\
\-\ of\\:\\ 0\\.003780359317928828\ \(0\)\
\-\ from\\:\\ 0\\.0037357985638767324\ \(0\)\
\-\ in\\:\\ 0\\.0037291790277898668\ \(0\)\
\-\ ct\\:\\ 0\\.003525969479032575\ \(0\)\
\-\ is\\:\\ 0\\.003317349724983632\ \(0\)\
\-\ the\\:\\ 0\\.0032625199930059186\ \(0\)\
\-\ or\\:\\ 0\\.002954344392223326\ \(0\)\
\-\ year\\:\\ 0\\.0028203695258788046\ \(0\)\
\-\ right\\:\\ 0\\.0026596805578478367\ \(0\)\
\-\ old\\:\\ 0\\.002580928014342934\ \(0\)\
\-\ no\\:\\ 0\\.0025381833354094453\ \(0\)\
\-\ a\\:\\ 0\\.0023398218396377657\ \(0\)\
\-\ on\\:\\ 0\\.002135371717892118\ \(0\)\
\-\ \\.\\:\\ 0\\.001466057537943504\ \(0\)\
